Heidelberg University Hospital / NCT / DKFZ
Heidelberg is Germany's cancer research capital, home to the DKFZ (largest cancer research institute in Germany) and the NCT, and the birthplace of FAPI PET and the brain tumour methylation classifier.
Overview
Heidelberg University Hospital, with the National Center for Tumor Diseases and the German Cancer Research Center (DKFZ), is Germany's cancer research capital and ranks eighteenth in the Newsweek/Statista oncology list. Its record includes the FAPI PET tracers from Haberkorn, Giesel and Kratochwil, the first-in-human actinium-225 PSMA therapy, the Heidelberg Ion-Beam Therapy Center for carbon ions, the DKFZ brain tumour methylation classifier from Pfister and von Deimling, and the MASTER precision oncology programme, with Stefan Fröhling among its leaders. Nuclide links it to FAP and PSMA as targets, to SOFIE Biosciences, to the first vaccine trial against shared neoantigens of mismatch-repair-deficient cancers, and to ideas for a university cyclotron network and core-funded radiotherapy trials. Turning tracers into approved therapies at scale is the open problem. The DKFZ has its own page.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Heidelberg University, including child institutions. 2,172 works · 30,102 citations · 77% open access · 9% clinical trials · 3% reviews.
- Hermann Brenner144 works
- Thilo Hackert131 works
- Michael Hoffmeister104 works
- Jessica C. Hassel88 works
- Markus Wolfgang Büchler82 works
- Karen Steindorf73 works
- Friedegund Elke Meier67 works
- Dirk Schadendorf63 works
- Joachim Wiskemann59 works
- Martin Loos59 works
- FAPI PET
- Alpha PSMA therapy
- Carbon-ion therapy
- CNS methylation classifier
- DKFZ basic research
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Similar pages
not linked directly; found by shared links- Pairing177Lu-PSMA-617 then 225Ac-PSMA rescue therapy
Shares Clemens Kratochwil, Uwe Haberkorn, PSMA, Targeted alpha therapy.
- Key paper225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer
Shares Clemens Kratochwil, Uwe Haberkorn, PSMA, Targeted alpha therapy.
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares A university cyclotron network with shared regulatory files for new tracers, FAP, FAPI PET, Targeted alpha therapy.
- JournalJournal of Nuclear Medicine
Shares Frederik Giesel, Clemens Kratochwil, Uwe Haberkorn, Actinium-225.
- PersonKen Herrmann
Shares European Association of Nuclear Medicine, FAP, FAPI PET, PSMA.
- CompanyRatio Therapeutics
Shares FAP, Targeted alpha therapy, Actinium-225.
- AgentFAP-2286 (177Lu / 68Ga)
Shares University Hospital Düsseldorf / CIO Düsseldorf, Uwe Haberkorn, FAP, FAPI PET.
- CompanyFull-Life Technologies
Shares PSMA, Targeted alpha therapy, Actinium-225.